Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02649478 · ClinicalTrials.gov registry record · NA
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A NA study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 1,430
- Enrollment target
NCT02649478 is a NA study that has completed, run by Roxane Laboratories. The registered enrollment target is 1,430 participants.
The verdict
NCT02649478, a NA study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,430 participants
- Enrollment target
Study Summary
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma
Interventions
- DRUG Placebo
- DRUG Fluticasone / Salmeterol
- DRUG Advair Diskus 100/50
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,430 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02649478
The ClinicalTrials.gov registry entry for NCT02649478 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02649478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02649478 about?
NCT02649478 is a clinical study titled "Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate". A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma
What is the current status of trial NCT02649478?
This trial is currently completed. It is a NA study. The enrollment target is 1,430 participants. The study started on 2014-08. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02649478?
The interventions under investigation include: Placebo (DRUG), Fluticasone / Salmeterol (DRUG), Advair Diskus 100/50 (DRUG).
Who is sponsoring clinical trial NCT02649478?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.